newsfilter
← Latest News
GlobeNewswire·

VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development

ZURICH, SWITZERLAND – June 24, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA")), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory